Elevance Health Inc.'s Stock Analysis

Elevance Health Reports Q2 2026 Financial Results and Guidance Update

Elevance Health, Inc. reported its financial results for the second quarter of 2026, revealing an operating revenue of $49.8 billion, a 0.8% increase from the same period in 2025. The company reported a diluted earnings per share (EPS) of $6.71 and an adjusted diluted EPS of $7.45, bolstered by favorable benefit expense performance. Additionally, the FY 2026 diluted EPS guidance was raised to at least $20.10, with adjusted diluted EPS guidance increased to at least $27.00, reflecting strong operational performance and targeted investments aimed at enhancing healthcare cost management and member experience.

The Health Benefits segment generated $42.7 billion in operating revenue, a 3% increase year-over-year, primarily due to higher premium yields. However, medical membership decreased to approximately 44.9 million, reflecting anticipated declines in certain segments. The company also reported an operating cash flow of $1.9 billion for the quarter and announced a quarterly dividend of $1.72 per share, payable on September 25, 2026. As of June 30, 2026, Elevance Health had approximately $5.3 billion remaining in its Board-approved share repurchase authorization.

Jul 15, 2026 06:01:33

Elevance Health Reaffirms 2026 Earnings Guidance for Investors

Elevance Health, Inc. plans to engage with investors and analysts this week, during which company officers will reaffirm their earnings guidance for the full year 2026. The expected earnings are at least $19.85 per diluted share, which includes approximately $6.90 per diluted share of net unfavorable items. Excluding these items, the adjusted earnings are anticipated to be at least $26.75 per diluted share. Additionally, the company maintains a benefit expense ratio guidance of 90.2% plus or minus 50 basis points for the same year.

The company has outlined various risks and uncertainties that could affect its performance, including trends in healthcare costs, regulatory changes, and the impact of large-scale medical emergencies. These factors may influence the company’s financial results and operational capabilities. Investors are advised to consider these risks when evaluating the company’s future performance and to review additional disclosures in the company's reports filed with the SEC.

Jun 10, 2026 06:01:35

Elevance Health Annual Meeting Outcomes and Shareholder Votes

On May 13, 2026, Elevance Health held its Annual Meeting of Shareholders, with 194,441,339 shares of common stock represented, meeting the quorum requirement. Shareholders elected directors to serve three-year terms expiring in 2029, approved the advisory vote on executive compensation, and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

Additionally, a shareholder proposal requesting an independent study on the impact of prohibiting corporate contributions to partisan 527 tax-exempt political groups was not approved. The outcomes of these votes may influence investor perception and decisions regarding the company.

May 13, 2026 16:07:56

Elevance Health Reports First Quarter 2026 Financial Results

Elevance Health reported first-quarter operating revenue of $49.5 billion for the period ending March 31, 2026, marking a 1.5% increase from the previous year. The company achieved a diluted earnings per share (EPS) of $8.00, with an adjusted diluted EPS of $12.58, driven by strong operational performance and approximately $1 per share from non-recurring investment income. The company has raised its full-year guidance for adjusted diluted EPS to at least $26.75, reflecting expected improvements in business operations and cost management strategies.

The Health Benefits segment generated $42.5 billion in operating revenue, a 2.6% increase year-over-year, while Carelon reported $18.0 billion in revenue, up 7.9%. However, the operating gain for Carelon declined by 3.8% due to lower health plan membership. Elevance Health returned $1.5 billion to shareholders in the first quarter, including a quarterly dividend of $1.72 per share, and repurchased 3.7 million shares for $1.1 billion. The company’s cash flow from operations was $4.3 billion, significantly higher than the previous year.

Apr 22, 2026 06:02:28

Elevance Health Reaffirms 2026 Earnings and Benefit Expense Guidance

Elevance Health, Inc. plans to meet with investors and analysts to reaffirm its adjusted shareholders’ earnings guidance for the full year 2026, set at a minimum of $25.50 per diluted share. The company also confirmed its benefit expense ratio guidance for 2026 to be 90.2%, with a margin of plus or minus 50 basis points. This guidance takes into account potential sanctions from the Centers for Medicare & Medicaid Services, which may impact enrollment in its Medicare Advantage-Prescription Drug plans starting March 31, 2026.

The company noted that it cannot currently reconcile its adjusted earnings guidance to the generally accepted accounting principles (GAAP) measure of shareholders’ earnings due to uncertainties surrounding the financial implications of resolving the CMS sanctions. The inability to estimate these impacts may affect the company's financial outlook, and investors are advised to consider the risks associated with healthcare regulations, competitive pressures, and potential changes in market conditions that could influence Elevance Health's performance.

Mar 10, 2026 06:02:21

Elevance Health Faces Medicare Enrollment Suspension Due to Compliance Issues

Elevance Health, Inc. has been notified by the Centers for Medicare & Medicaid Services (CMS) of impending intermediate sanctions that will suspend enrollment of new Medicare beneficiaries into its Medicare Advantage-Prescription Drug plans. These sanctions are set to take effect on March 31, 2026, unless the company satisfactorily addresses the identified compliance issues related to Medicare Advantage risk adjustment data submissions prior to April 3, 2023. Current members' benefits will remain unaffected during this period.

The company has made revisions to its practices in April 2023 following additional regulatory guidance and is actively engaging with CMS to resolve the concerns raised. Investors should note that these developments could impact future enrollment and revenue from Medicare plans, as well as the company's overall compliance standing within the regulatory framework governing healthcare services.

Mar 02, 2026 06:03:41

Elevance Health Announces Management Changes and Earnings Guidance

Elevance Health has announced key management changes, including Peter D. Haytaian's transition from Executive Vice President and President of Carelon to Special Advisor effective May 4, 2026, due to family commitments. Mark Kaye, the current Chief Financial Officer, will expand his responsibilities to oversee Carelon, while Felicia Norwood will lead the consolidated Health Benefits organization. These changes aim to enhance decision-making and execution across the company’s operations.

The company reaffirmed its earnings guidance for the full year 2026, expecting at least $22.30 per diluted share, which includes approximately $3.20 per diluted share of net unfavorable items. Excluding these items, adjusted earnings are anticipated to be at least $25.50 per diluted share. Elevance Health also confirmed its benefit expense ratio guidance for the year as 90.2%, plus or minus 50 basis points.

Feb 26, 2026 14:59:29

Elevance Health Reports Q4 and Full Year 2025 Results

Elevance Health reported operating revenue of $49.3 billion for the fourth quarter of 2025, marking a 10% increase compared to the same period last year. For the full year 2025, the company achieved operating revenue of $197.6 billion, up 13% year-over-year, driven by higher premium yields and growth in Medicare Advantage membership, despite some attrition in its Medicaid business. The diluted earnings per share (EPS) for Q4 2025 was $2.47, with an adjusted diluted EPS of $3.33, while the full year diluted EPS stood at $25.21, with an adjusted EPS of $30.29. The company also reported a benefit expense ratio of 93.5% for Q4 2025, reflecting increased medical costs, particularly in its Affordable Care Act health plans.

In terms of cash flow, Elevance Health generated $4.3 billion in operating cash flow for 2025 and returned $4.1 billion to shareholders through share repurchases and dividends. The company declared a first quarter 2026 dividend of $1.72 per share, payable on March 25, 2026. Elevance Health's medical membership totaled approximately 45.2 million as of December 31, 2025, reflecting a slight decline due to Medicaid attrition. The company maintained a focus on expense discipline while investing in workforce and technology improvements, and it has a remaining share repurchase authorization of approximately $6.7 billion.

Jan 28, 2026 06:03:02

Elevance Health Appoints Amy Schulman as Independent Director

Elevance Health's Board of Directors has elected Amy W. Schulman as an independent director, effective January 12, 2026. Schulman will also serve on the Audit and Finance Committees. She is recognized for her expertise in healthcare innovation and governance, and has no material interest in any transactions that would require disclosure. Her appointment aligns with the company's strategy to ensure diverse leadership and enhance long-term value for shareholders.

Schulman currently holds the position of Managing Partner at Polaris Partners and has significant experience in the healthcare sector, including previous senior roles at Pfizer Inc. Her background in regulatory strategy and investment is expected to contribute to Elevance Health’s mission of improving health outcomes. The company serves 109 million consumers through a comprehensive range of healthcare solutions.

Dec 10, 2025 16:35:16

Elevance Health Reaffirms Earnings Guidance for 2025

Elevance Health, Inc. plans to engage with investors in the upcoming week, reaffirming its earnings guidance for the full year 2025 at approximately $24.70 per diluted share. This figure includes about $5.30 per diluted share of net unfavorable items. Excluding these items, the company anticipates adjusted earnings to be around $30.00 per diluted share. Additionally, the benefit expense ratio guidance for 2025 is expected to be approximately 90.0%, reflecting the company's assessment of current market conditions and operational performance.

The company's expectations are based on various factors, including cost trends and medical claims payable estimates. However, management cautions that actual results may vary significantly if business conditions or assumptions change. The document also outlines several risks that could impact the company’s performance, such as healthcare cost trends, regulatory changes, and operational challenges, which may influence investor decisions.

Nov 10, 2025 17:03:08